Within the first strategy, Haber and colleagues conjugated tPA molecules to an anti-fibrin monoclonal antibody and achieved successful fibrinolysis in a rabbit thrombosis model with an overall 3-fold increase in potency, as compared to free tPA. 9 Collen et al. developed a series of antibodies against activated platelets which were used in vitro and in vivo for treating platelet rich clots. 10 The group of Yang devised a modular approach for originating thrombolytic compounds resulting from the electrostatic interaction between a negatively charged heparin-antifibrin complex and a modified tPA molecule. 11, 12 Although these specifically targeted molecular agents have been demonstrated over 15 years ago, their clinical application has been limited, likely, for their complexity, stability, immunogenicity, and reduced thrombolytic activity as compared to the original free active molecule. 13 More recently, nanoparticles have been proposed as an alternative strategy. After the pioneering work of Heeremans and colleagues, who loaded tPA molecules in the aqueous core of conventional liposomes showing a 5-fold increase in thrombolytic potency, 14 a variety of nanoparticles with clotspecific targeting ability and triggered release of thrombolytic agents have been demonstrated. [15] [16] [17] For instance, the group of Lanza and Wickline prepared fibrin-targeted liquid perfluorocarbon nanoparticles for the delivery of streptokinase demonstrating in vitro enhanced thrombolysis upon ultrasound stimulation. 15 Vaidya et al. developed target-sensitive liposomes that would rapidly release tPA in the presence of activated platelets, thus realizing a selective drug release. 16 Pegylated liposomes were used to increase up to 20-times the half-life of tPA in the circulation. 17 Recently, the group of Letourneur demonstrated that fucoidan-labeled polymeric nanoparticles exhibit a strong tropism for the clot fibrin network and facilitate vessel recanalization. 18 Non-organic nanoparticles have also been used for thrombolysis. Clusters of iron oxide nanocubes, coated and stabilized by a tPA multi-layer, were proposed by the authors for the combined chemical and thermal treatment of blood clots upon stimulation with exogenous alternating magnetic fields. 19 Ultrasmall superparamagnetic iron oxide nanoparticles, coated with fucoidan, were proposed for the magnetic resonance imaging (MRI) of blood clots. 20 The team led by Kim developed fibrin-targeted glycol chitosan-coated gold nanoparticles for assessing the clot stability via computed tomography (CT) imaging. 21 The advantage of nanoparticles over the free or targeted tPA stays in the larger amounts of lytic agents that could be deployed at the clot site; the multivalent adhesive interactions with the clot surface; the higher stability and longer circulation half-life in vivo; the ability to trigger the release via exogenous and endogenous stimuli, and to image and treat clots simultaneously.
Micron-sized particles and blood cells have been also proposed for the specific delivery of thrombolytic molecules to blood clots. A notable example is given by the work of Korin and colleagues who developed  4 µm spherical polymeric microparticles resulting from the aggregation of multiple, smaller  200 nm tPA-carrying nanoparticles. The microscale aggregates were shown to be intact under physiological flow conditions and break apart under high shear stresses (> 100 dyne/cm 2 ), which are typical of partially occluded vessels. 22 Although these shear-activated particles induced a 3-fold faster vessel recanalization in abdominal clots and rescued almost all tested mice with pulmonary emboli, they exhibited a short circulation half-life (< 5 min), which is comparable to free tPA, and a rapid accumulation in the liver (> 70 % ID/g). At even a larger scale, erythrocytes (RBCs) were elegantly used by the group of Muzykantov to deliver thrombolytic agents to nascent clots. [23] [24] [25] These blood cells have a characteristic size of  7 µm but their deformability allows them to squeeze through the smallest capillaries in the lungs and splenic parenchyma, supporting their circulation for several days. Indeed, tPA-RBCs cannot infiltrate or firmly attach onto mature clots, because of their large size. However, they can certainly impair the formation of new clots and, as such, were proposed for thromboprophylaxis rather than for acute treatments. 23 Moreover, the large size of tPA-RBCs prevented the accumulation of free tPA within the brain tissue, dramatically reducing the risk of cerebral hemorrhages. 25 Indeed, a major technical challenge for the clinical implementation of this approach is the coupling of tPA with autologous RBCs and their reinjection into the patient.
In this work, tPA molecules are conjugated to the polymeric structure of soft, long circulating discoidal nanoconstructs (tPA-DPNs), which would mimic erythrocytes. 26 These polymeric nanoconstructs are made out of a mixture of poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) and present a diameter of 1,000 nm and a height of 400 nm. tPA molecules are covalently linked to the carboxyl groups exposed on the PLGA chains. In the sequel, the synthesis and stability of tPA-DPNs is first discussed, followed by the in vitro characterization of their clot dissolution potency. This is performed under static conditions and in an ad-hoc two-channel microfluidic chip where whole blood clots are generated and exposed to a tPA-DPN solution under continuous flow (dynamic conditions).
Finally, the in vivo efficacy of tPA-DPNs is assessed in a mouse thrombosis model where blood clots are induced in mesentery venules. For all experiments, the lytic potential of tPA-DPNs is directly compared to free tPA and 200 nm spherical polymeric nanoconstructs (tPA-SPNs), made of PLGA and decorated on the surface with tPA molecules.
RESULTS
Synthesis and Characterization of tPA-DPNs. The synthesis of DPNs is a multistep, top-down process. [26] [27] [28] Briefly, laser writing lithography is used to realize a pattern with billions of wells, reproducing the characteristic geometry of DPNs, in a silicon master template (Supporting Figure.1A ).
Then, via replica molding, this template is used to generate an intermediate PDMS template
(Supporting Figure.1B ) and eventually a sacrificial PVA template (Supporting Figure.1C ). In the current configuration, DPNs are circular disks with a diameter of 1,000 nm, a height of 400 nm, and are composed by an homogeneous mixture of Poly(D,L-lactide-co-glycolide)-acid carboxylic terminated (PLGA-COOH) and poly(ethylene glycol) diacrylate (PEG-DA) ( Figure.1A ). Note that these polymers are among the most studied and best characterized polymers for biomedical applications, and have been approved by various regulatory agencies for diverse clinical applications. 29, 30 This polymeric mixture, together with a photoinitiator, is deposited into the wells of the PVA template and exposed to a UV-light source for crosslinking. After polymerization, the sacrificial PVA template is dissolved into an aqueous solution at room temperature, under gentle stirring, and, upon centrifugation and filtration, DPNs are collected. Note that DPNs are hydrogel-based particles with a porous structure. Finally tPA is directly associated to the resuspended DPNs. Specifically, the carboxylic groups on the PLGA chains are activated, via an EDC/NHS reaction, and then covalently coupled to one of the amine groups on the tPA molecules (Supporting Figure.1D ). A schematic representation of tPA-DPNs is depicted in Figure. 1A.
The geometrical features of DPNs and tPA-DPNs were assessed via a Multisizer Particle Counter, a Zetasizer Nano, electron microscopy, and atomic force microscopy ( Figure. 1B-E). The Multisizer Particle Counter spectra for the DPNs and tPA-DPNs are almost perfectly overlapped, as shown in Figure. 1B (orange: tPA-DPNs; green: empty DPNs). After the reaction with tPA, DPNs presented a negligible increase in average size (< 3 %), from 784 + 10 nm (DPNs) to 803 + 15 nm (tPA-DPNs). On the other hand, the change in surface ζ potential was more relevant, increasing from a negative value of -21 + 0.6 mV for DPNs to a positive value of 16 + 0.4 mV for tPA-DPNs. This large variation in surface ζ potential has to be ascribed to the tPA conjugation with the carboxylic groups presented on the PLGA chains and the progressive neutralization of the originally negative surface electrostatic charge of DPNs. As such, the change in surface ζ potential can be also used as an indirect method to quantify the efficiency of tPA conjugation. A representative Transmission electron Microscopy (TEM) image of DPNs is given in Figure. 1C, which confirms the discoidal shape with a circular base of about 1 µm in diameter. In the same figure, the upper-left inset shows an image deriving from the superimposition of an electron microscopy and a fluorescent microscopy picture for the same DPN, which was loaded with lipid-Rhodamine B (RhB). A Scanning Electron Microscopy (SEM) image and an Atomic Force Microscopy (AFM) image of DPNs are given in Figure. 1D-E, respectively, which document a DPN diameter of  1.2 µm, for both SEM and AFM, and height of  347 nm for SEM and  300 nm for AFM. Finally, as depicted in Figure. 1F, tPA-DPNs were demonstrated to be geometrically stable, upon storage in saline at 37° C, with an overall variation in diameter of 6 % over six days.
The pharmacological properties of DPNs were characterized for the tPA encapsulation efficiency and release profile ( Figure. 2). First, to confirm the firm conjugation of the thrombolytic agent to the particle structure, DPNs were grafted with FITC-tPA and loaded with lipid-RhB. This fluorescent lipid was dispersed uniformly within the PLGA/PEG matrix before particle synthesis. In Figure. 2A, projections of tridimensional confocal microscopy images show the green fluorescence associated with FITC-tPA properly co-localized with the red fluorescence given by the lipid-RhB. The full reconstruction is presented in the Supporting Figure. 2. This also demonstrates the ability to load multiple agents within the tPA-DPN matrix. Moreover, in order to assess the tPA encapsulation efficiency, 5 x 10 8 DPNs were incubated with different amounts of tPA, ranging from 10 to 70 µg. As depicted in Figure. 2B, the amount of tPA conjugated to DPNs grows linearly with the input dose returning an almost 1:1 ratio (dashed line), thus implying an encapsulation efficiency close to 100 %.
For 5 x 10 8 DPNs, saturation is reached at about 60 µg of tPA. Indeed, the total tPA amount can be finely tuned by changing the number of DPNs. Given the hydrogel nature of these DPNs, tPA molecules are expected to react with the PLGA-COOH groups exposed on the surface as well as those available within the polymer matrix. Finally, the possible release of tPA from DPNs was analyzed upon particle incubation in PBS, at 37° C, up to 72 h. Figure.2C shows that the largest majority of tPA (i.e. > 90%) is associated with the DPN structure throughout the observation period, which demonstrates the stable conjugation of the lytic agent. It is here important to highlight that this feature of tPA-DPNs together with their relatively large size would limit the non-specific accumulation of tPA molecules within the brain parenchyma and possibly reduce the risk of hemorrhagic events.
To assess if the conjugation of tPA to the DPNs surface affects the activity of the drug, an enzymatic assay of free and conjugated tPA was performed. This in vitro assay measures the ability of tPA to activate the plasminogen to plasmin, using a plasmin substrate releasing a yellow para-nitroaniline (pNA) chromophore. Three different concentrations were tested, namely 10, 20, and 50 µg/ml of drug, up to 2 h. As depicted in Figure. 2D, the activity of tPA after the conjugation with the carboxylic group of PLGA is retained. No statistically significant difference is observed between free or bound tPA.
For comparison, Spherical polymeric nanoconstructs (SPNs) were also prepared. These nanoparticles comprise a PLGA core and a lipid surface layer, and are synthesized via an emulsion technique, as described in the Supporting Information. Similarly to tPA-DPNs, carboxylic groups exposed on the SPN surface are activated, via an EDC/NHS reaction, and then covalently coupled to the amine groups on the tPA molecules returning the tPA-SPNs. These conventional nanoconstructs have a spherical
shape with a diameter of 240  0.2 nm and a surface potential  = -8  0.6 mV. Dynamic light scattering data and scanning electron microscopy images are provided in Supporting Figure. 3.
In vitro efficacy of tPA-DPNs under static conditions. After characterizing the physico-chemical properties of tPA-loaded nanoparticles, their dissolution potential was assessed on fresh blood clots.
First, a static experiment was performed in order to confirm that tPA would preserve its thrombolytic activity even after direct conjugation. Whole blood was collected from rats and immediately incubated with a thrombin solution to induce rapid clot formation. After maturation, clots were transferred in a 24-multi-well dish and treated with PBS (control), free tPA, SPNs, tPA-SPNs, DPNs, and tPA-DPNs. The same dose of tPA (30 µg/ml) was used for all conditions. Until now, all dissolution tests were performed in PBS which lacks blood proteins such as albumin, hormones, and others macromolecules that could adsorb on the particle surface and interfere with the lytic process or even directly affect the stability of tPA. Therefore, dissolution experiments were also performed in the presence of 100 % fetal bovine serum (FBS) and data are reported in Figure. Unexpectedly, even after 3 h of incubation with serum proteins in FBS, over 70 % of the thrombolytic activity of tPA-DPNs is retained, as compared to fresh free tPA. This is an interesting result, given that free tPA has a very short stability in blood. In the case of tPA-SPNs, a 50 % reduction in lytic activity is registered within the first 30 min of incubation followed by a steady slow decrease for longer incubations. Indeed, thrombolytic molecules are directly exposed on the nanoparticle surface in tPASPNs and immediately accessible by blood proteins. In contrast, the thrombolytic molecule is distributed within the hydrogel porous matrix of the nanoconstructs in tPA-DPNs. These results would suggest that the surface adsorption of blood proteins, which happens within the first minute following FBS exposure, is not significantly affecting the activity of tPA associated with DPNs.
In vitro efficacy of tPA-DPNs under dynamic conditions. The thrombolytic activity of tPA-DPNs was also evaluated under dynamic conditions. For the formation and dissolution of blood clots, a microfluidic chip was fabricated consisting of two parallel channels separated in the middle by a row of pillars (Supporting Figure.4A ). 31 Whole blood was flowed in the bottom channel while an aqueous solution of thrombin with the addition of CaCl 2 , was infused in the upper channel ( Figure. 5A, left).
Since whole blood was collected in tubes containing sodium citrate, the CaCl 2 added to the thrombin solution was used to reactivate the process only within the microfluidic chip. The infusion of the two solutions was controlled via a syringe pump. The pro-coagulant solution encounters whole blood in the middle of the chip where the row of pillars facilitates their mixing and the spontaneous formation of the blood clot, as depicted in Figure. 5A (right) and in the Supporting Movie.1.
The so-formed clots were treated with PBS, SPNs, DPNs, free tPA, tPA-SPNs, and tPA-DPNs, using the same dose as per the static experiments (i.e. 30 µg/ml). After clot formation, thrombolytic solutions were infused in both the upper and lower channels at 100 nl/min, for flow conditions comparable to that of human arterioles. The fluidic experiments were performed in a micro-environmental chamber placed on the stage of a time-lapse microscope, preserving a constant temperature at 37° C and clots were monitored for 2 h continuously. In contrast to static experiments, clots form spontaneously within the microfluidic chips and, similarly to in vivo experiments, their initial size cannot be precisely Importantly, the two tPA nanoconstructs (tPA-SPNs and tPA-DPNs) show a more efficient dissolution of the blood clots as compared to free tPA. Already at 60 min post treatment initiation, the clot size reduces down to 57 + 8 % for tPA-DPNs and 42 + 10 % for tPA-SPNs against 83 + 10 % for free tPA.
These numbers decrease even more at 90 and 120 min, being respectively 34 + 7 % and 28 + 12 % for the tPA-DPNs and 24 + 3 % and 17 + 6 % for the tPA-SPNs against 56 + 21 % and 44 + 19 % for free tPA ( Figure.5D ). As depicted in Figure. 5E, the dissolution rates of tPA-SPNs and tPA-DPNs are significantly higher than for free tPA. At 60 min post treatment initiation, the dissolution rate of tPA-DPNs is over 2-fold higher than for free tPA and 50% higher than for tPA-SPNs. At 30 min, tPA-SPNs present a dissolution rate which is two times larger than for tPA-DPNs. Both Figure. 5D and E document a faster clot dissolution within the first 60 to 90 min post-treatment initiation for tPA-DPNs over free tPA. This is indeed a key feature of this nano-thrombolytic agent as compared to the molecular tPA.
The higher efficacy observed for tPA-DPNs over free tPA should be ascribed to the fact that DPNs are large enough and deformable to efficiently deposit on the clot surface and be entrapped within the fibrin network. This would increase the residence time of tPA in the clot proximity and thus enhance the lytic activity of the nano-agent. On the other hand, the molecular form of tPA would be rapidly washed away, thus providing a limited the temporal interaction with the blood clot. This was confirmed by infusing within the microfluidic chip RhB-DPNs and monitoring their interaction dynamics with blood clots with an epifluorescent microscope. The Supporting Movie.6 demonstrates the progressive accumulation of the RhB-DPNs (red labeled) on and around the blood clot. Although this movie confirms the ability of DPNs to passively interact with the clot network, it should be also kept in mind that tPA has a direct affinity for fibrin. 9 Moreover, discoidal particles have been shown in multiple studies to enhance adhesion under flow. [32] [33] [34] Thus, the observed accumulation of tPA-DPNs at the clot site could also result from the appropriate combination of tPA-mediated specific adhesion with DPN geometry. On the other hand, the faster dissolution rates associated with tPA-SPNs at earlier time points should be ascribed to the ability of these smaller particles to infiltrate the fibrin network of the clot and the direct exposure of the tPA molecules on the SPN surface.
In vivo efficacy of tPA-DPNs. A thrombosis model was established in C57BL/6 mice by inducing a localized vascular injury. Specifically, a filter paper was soaked in a FeCl 3 solution and then applied over the surface of an isolated venule in the murine mesentery circulation. 18, 19 In few seconds, a blood clot was locally generated as documented by intravital microscopy (Supporting Movie.7). After thrombus formation, 200 l of treatment solutions were retro-orbitally injected. The temporal evolution of the blood clot was followed in response to seven treatment groups: DPNs, SPNs, 1 mg/kg free tPA, 2.5 mg/kg free tPA, 1 mg/kg tPA-SPNs, 2.5 mg/kg tPA-SPNs, 1 mg/kg tPA-DPNs, and 2.5 mg/kg tPA-DPNs. Platelets and leukocytes were labelled in red with an injection of Rhodamine 6G. for 1 mg/kg tPA-DPNs, the area reduces to 78  3 %, and down to 58  8 % for 2.5 mg/kg tPA-DPNs.
Interestingly, tPA-SPNs induce a clot area reduction which is comparable to that of free tPA: 92  2 % for 1 mg/kg tPA-SPNs and 86  2 % for 2.5 mg/kg tPA-SPNs. The difference in area reduction is statistically significant for the two different tPA doses within all three groups (free tPA, tPA-SPNs and tPA-DPN) demonstrating that the increase in tPA dose from 1 to 2.5 mg/kg is effective. Also, the difference in area reduction is statistically significant between free tPA and tPA-DPNs at each of the two tPA doses, demonstrating that tPA conjugation to the DPN structures always enhances the thrombolytic activity of the clinical agent. Although, tPA-SPNs were capable of dissolving clots in vitro more rapidly than tPA-DPNs ( Figures.4E and D) , they did not show in vivo any significant advantage over free tPA. This should be ascribed to the more efficient circulation profiles of tPA-DPNs.
It is here important to highlight that in humans, the administered dose of tPA is of about 1 mg/kg, depending on the duration of the infusion. 35 Using an animal equivalent dose calculation based on the body area, 36 this would correspond to over 10 mg/kg in mice. Given the thrombolytic potency of tPADPNs even at 1 mg/kg of tPA, it can be inferred that these nano-thrombolytic agent would be at least 10-fold more effective than the clinical formulation.
DISCUSSION
From the above results, key distinctive features of tPA-DPNs over its free molecular form (tPA) and the nanometric spherical counterpart (tPA-SPNs) can be readily deduced: firstly, the efficient and stable association of tPA with the DPN polymeric structure; secondly, the size, shape and deformability combination favoring deposition within blood clots; and thirdly, the rapid dissolution of fibrin based vascular occlusions.
As shown in Figures.2A-B , DPNs can be associated with tPA returning a loading efficiency close to 100 %. This is achieved by using the available clinical formulation of tPA, with no additional modification or purification steps. Furthermore, the association is highly stable, as demonstrated in Figure. 2C, whereby less than 10 % of the conjugated tPA would detach from the DPN structure and be freely released in the blood stream. This stable association together with the micrometric size of DPNs would limit their accumulation within the brain parenchyma, even in the presence of a hyperpermeable vascular bed. Indeed, this could be crucial in preventing the occurrence of the dramatic side effects associated with the systemic administration of tPA, in line with what has been documented by Muzykantov and colleagues for the large tPA-RBCs. 25 Notice that a similar behavior would not be expected for the 200 nm tPA-SPNs, which would likely extravasate with their tPA load at sites of vascular hyper-permeability.
In addition to the conjugation stability, the lytic activity and geometrical features of tPA-DPNs appears to be retained quite efficiently even after exposure to serum proteins. This could explain the retained lytic activity whereby the outer most tPA molecules would undergo degradation followed by the inner most tPA molecules. Indeed, this can also be inferred by analyzing the data in Figure. 4D for the tPA-SPNs. In these spherical nanoconstructs, tPA molecules are all exposed on the surface and, consequently, the tPA-SPN lytic activity decreases abruptly to 30 % within the first 30 min. It is here important to note that the slightly positive surface charge of tPADPNs should be mostly ascribed to the neutralization of the surface PLGA-COOH groups and can be finely tuned by modulating tPA loading (Supporting Figure.6 ).
Another attribute of tPA-DPNs is their size, shape and deformability combination. The DPN geometry has been selected for its higher efficacy in adhering at surfaces under flow. This has been demonstrated, by the authors and other researchers, using in silico computational models, in vitro fluidic chips, and in vivo small animal experiments. 32-34, 37, 38 Briefly, the efficient adhesion of discoidal nanoparticles to blood clots would result from the fine balance between wall adhesive interactions, which are enhanced by the large discoidal surface, and the dislodging hydrodynamic forces, which are reduced by the thin cross section of the particles. Although, in the current configuration, tPA-DPNs do not carry any targeting moiety for blood clots, it should be recalled that tPA has a significant affinity for fibrin. Thus, specific adhesive interactions could arise at the interface between a tPA-DPN and the fibrin network in the clot. Importantly, this adhesive interaction would involve simultaneously multiple tPA molecules (multivalent interaction) exposed over the large discoidal DPN surface.
Furthermore, differently from conventional nano-thrombolytic agents, tPA-DPNs are made using the so-called 'soft' version of DPNs. These particles have a Young's modulus ranging between a few tens to a few hundreds of kPa. 28 The deformability of tPA-DPNs would favor their deposition within the complex fibrin network of the blood clot, thus providing an additional mechanism of accumulation. Furthermore, tPA distributes quite uniformly throughout the whole DPN porous matrix, with some tPA molecules directly exposed over the nanoconstruct surface whereas others would be embedded within them. Likely, this would explain the preserved lytic activity of tPA-DPNs upon exposure to serum proteins. Under dynamic conditions, in microfluidic chips, tPA-DPNs outperform free tPA molecules offering a faster degradation rate, which is indeed a crucial feature for any thrombolytic agent. In preclinical mouse experiments, tPA-DPNs were observed to dissolve clots more efficiently than free tPA at concentrations of both 1.0 and 2.5 mg/kg, which are 4 to 10 times lower than the clinical values. In contrast, no significant improvements over free tPA were documented in vivo for the 200 nm tPA-spherical PNs. In summary, the higher stability together with the more effective and faster dissolution of tPA-DPNs over free tPA, would make these constructs a promising nanotechnological platform for the treatment of acute thrombotic events. Thrombin were purchased from Sigma-Aldrich (Missouri, USA). Rhodamin-B (lipid-RhodB) was purchased from Avanti Polar Lipids (Alabama, USA). tPA was provided by Ospedale Galliera, (Liguria, IT). Bicinchoninic protein assay dye kit was purchased from BioRad (California, USA). All the reagents and other solvents were used without further purification.
MATERIALS AND METHODS

Chemicals. Polydimethylsiloxane (PDMS) (Sylgard
Synthesis of Discoidal Polymeric Nanoconstructs (DPNs) coated with tissue Plasminogen Activator
(tPA). Particles were synthesized using a top down approach previously described. 26, 28 Briefly, a silicon master template was fabricated using a Laser Writer Lithography technique which allows to transfer on the silicon a specific pattern made out of discoidal wells with a diameter and a height characteristic for the nanoparticles. Then, a polydimethylsiloxane (PDMS -Sylgard 184) solution was transferred onto the master to obtain a template with the opposite shape of the Si master. After 4 h of polymerization at 60° C, PDMS was peeled away and the cylindrical pillars on the template were covered with a poly(vinyl alcohol) (PVA) solution and left in the oven at 60° C for 3 h. Once polymerized, the sacrificial PVA template presented the same cylindrical wells of the original Si master.
DPNs are composed by a mixture of (poly(lactic acid-co-glycolic acid) (PLGA) and poly(ethylene glycol) diacrylate (PEG diacrylate) polymers. 30 mg of PLGA were dissolved in 600 μl of dichloromethane and chloroform, and mixed with 6 mg of PEG. Then, 0,6 mg of a photo-initiator (2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone) were added into the polymeric solution to allow a further polymerization of PEG diacrylate. The polymeric mixture was spread into the PVA wells and the loaded templates were then exposed to UV-light for 10 min. Hydrophilic PVA templates were dissolved in deionized water for 3 h under stirring conditions at room temperature. Nanoparticles were released from the wells of PVA, and then collected through centrifugation (3,900 rpm for 20 min) and purified from PVA debris with 2 μm filters. Enzymatic Activity Test. tPA activity was tested after the conjugation to DPNs using a chromogenic activity assay test (abcam108905). Particles were synthesized and incubated up to 2 h with the assay mix composed by plasminogen and plasmin substrate. The assay measures the ability of Tissue type Plasminogen Activator to activate the plasminogen to plasmin. The amount of plasmin produced is measured using a specific plasmin substrate releasing a yellow para-nitroaniline (pNA) chromophore.
Purified DPNs were incubated with EDC/NHS -in a molar
The change in absorbance of the pNA in the reaction solution at 405 nm is directly proportional to the Tissue type Plasminogen Activator enzymatic activity. In vitro efficacy of tPA-DPNs and tPA-SPNs in dynamic condition. The chips were fabricated by using a replica molding approach as previously described. 31 It consists in two lithographic steps (etching of the pillars and etching of the whole chip) for the creation of a silicon master that was then 
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